{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:07:35Z","timestamp":1794917255724,"version":"4.9.1"},"reference-count":135,"publisher":"Bentham Science Publishers Ltd.","issue":"9","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>In the central nervous system (CNS), a specific loss of focal neurons leads to mental and\nneurological disorders like dementia, Alzheimer\u2019s disease (AD), Huntington\u2019s disease, Parkinson\u2019s\ndisease, etc. AD is a neurological degenerative disorder, which is progressive and irreversible in nature\nand is the widely recognized reason for dementia in the geriatric populace. It affects 10% of\npeople above the age of 65 and is the fourth driving reason for death in the United States. Numerous\nevidence suggests that the neuronal compartment is not the only genesis of AD, but transcription\nfactors also hold significant importance in the occurrence and advancement of the disease. It is\nthe need of the time to find the novel molecular targets and new techniques for treating or slowing\ndown the progression of neurological disorders, especially AD. In this article, we summarised a\nconceivable association between transcriptional factors and their defensive measures against neurodegeneration\nand AD. The mammalian forkhead transcription factors of the class O (FoxO) illustrate\none of the potential objectives for the development of new methodologies against AD and\nother neurocognitive disorders. The presence of FoxO is easily noticeable in the \u201ccognitive centers\u201d\nof the brain, specifically in the amygdala, hippocampus, and the nucleus accumbens. FoxO\nproteins are the prominent and necessary factors in memory formation and cognitive functions.\nFoxO also assumes a pertinent role in the protection of multiple cells in the brain by controlling the\ninvolving mechanism of autophagy and apoptosis and also modulates the process of phosphorylation\nof the targeted protein, thus FoxO must be a putative target in the mitigation of AD. This review\nfeatures the role of FoxO as an important biomarker and potential new targets for the treatment\nof AD.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527319666201001105553","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T13:24:37Z","timestamp":1601558677000},"page":"709-721","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer\u2019s Disease"],"prefix":"10.2174","volume":"19","author":[{"given":"Shikha","family":"Goswami","sequence":"first","affiliation":[{"name":"Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozaifa","family":"Kareem","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Faculty of Applied Sciences and Technology, University of Kashmir, Srinagar, JK, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K.","family":"Goyal","sequence":"additional","affiliation":[{"name":"Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed M.","family":"Mumtaz","sequence":"additional","affiliation":[{"name":"Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv K.","family":"Tonk","sequence":"additional","affiliation":[{"name":"Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Gupta","sequence":"additional","affiliation":[{"name":"Delhi Pharmaceutical Sciences and Research University, Mehrauli- Badarpur Rd, Sector 3, PushpVihar, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faheem H.","family":"Pottoo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University P.O.BOX 1982, Dammam 31441, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature09782","volume":"469","author":"Levine B.","year":"2011","unstructured":"Levine B.; Mizushima N.; Virgin H.W.; Autophagy in immunity and inflammation. Nature 2011,469(7330),323-335","journal-title":"Nature"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.2174\/1568026620666200228095553","volume":"20","author":"Sharma P.","year":"2020","unstructured":"Sharma P.; Sharma A.; Fayaz F.; Wakode S.; Pottoo F.H.; Biological signatures of Alzheimer\u2019s disease. Curr Top Med Chem 2020,20(9),770-781","journal-title":"Curr Top Med Chem"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"Kim J.","year":"2009","unstructured":"Kim J.; Basak J.M.; Holtzman D.M.; The role of apolipoprotein E in Alzheimer\u2019s disease. Neuron 2009,63(3),287-303","journal-title":"Neuron"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1111\/ejn.14838","volume":"52","author":"Ibrahim A.M.","year":"2020","unstructured":"Ibrahim A.M.; Pottoo F.H.; Dahiya E.S.; Khan F.A.; Kumar J.B.S.; Neuron-glia interactions: molecular basis of Alzheimer\u2019s disease and applications of neuroproteomics. Eur J Neurosci 2020,52(2),2931-2943","journal-title":"Eur J Neurosci"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1086\/302553","volume":"65","author":"Campion D.","year":"1999","unstructured":"Campion D.; Dumanchin C.; Hannequin D.; Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999,65(3),664-670","journal-title":"Am J Hum Genet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.arcmed.2012.11.009","volume":"43","author":"Mendez M.F.","year":"2012","unstructured":"Mendez M.F.; Early-onset Alzheimer\u2019s disease: nonamnestic subtypes and type 2 AD. Arch Med Res 2012,43(8),677-685","journal-title":"Arch Med Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4018\/978-1-7998-1317-0.ch001","author":"Akhter Y.","year":"2020","unstructured":"Akhter Y.; Nabi J.; Hamid H.; Tabassum N.; Pottoo F.H.; Sharma A.; Protein quality control in neurodegeneration and neuroprotection. Quality Control of Cellular Protein in Neurodegenerative Disorders 2020,1-24","journal-title":"Quality Control of Cellular Protein in Neurodegenerative Disorders"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-018-0394-7","volume":"10","author":"Vargas D.M.","year":"2018","unstructured":"Vargas D.M.; De Bastiani M.A.; Zimmer E.R.; Klamt F.; Alzheimer\u2019s disease master regulators analysis: search for potential molecular targets and drug repositioning candidates. Alzheimers Res Ther 2018,10(1),59","journal-title":"Alzheimers Res Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/hmg\/9.16.2383","volume":"9","author":"Theuns J.","year":"2000","unstructured":"Theuns J.; Van Broeckhoven C.; Transcriptional regulation of Alzheimer\u2019s disease genes: implications for susceptibility. Hum Mol Genet 2000,9(16),2383-2394","journal-title":"Hum Mol Genet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"Anand R","year":"2014","unstructured":"Anand R; Gill K D; Mahdi A A; Therapeutics of Alzheimer\u2019s disease: past, present and future. Neuropharmacology 2014,76(Pt A),27-50","journal-title":"Neuropharmacology"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"Goate A.","year":"1991","unstructured":"Goate A.; Chartier-Harlin M.C.; Mullan M.; Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature 1991,349(6311),704-706","journal-title":"Nature"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1471-4159.2004.02581.x","volume":"90","author":"Irizarry M.C.","year":"2004","unstructured":"Irizarry M.C.; Deng A.; Lleo A.; Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. J Neurochem 2004,90(5),1132-1143","journal-title":"J Neurochem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"Corder E.H.","year":"1993","unstructured":"Corder E.H.; Saunders A.M.; Strittmatter W.J.; Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 1993,261(5123),921-923","journal-title":"Science"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"Corder E.H.","year":"1994","unstructured":"Corder E.H.; Saunders A.M.; Risch N.J.; Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994,7(2),180-184","journal-title":"Nat Genet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"32240","DOI":"10.1074\/jbc.M603106200","volume":"281","author":"Hiltunen M.","year":"2006","unstructured":"Hiltunen M.; Lu A.; Thomas A.V.; Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. J Biol Chem 2006,281(43),32240-32253","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/JAMPS\/2016\/24441","volume":"10","author":"Nigar S.","year":"2016","unstructured":"Nigar S.; Pottoo F.; Tabassum N.; Verma S.; Javed M.; Molecular insights into the role of inflammation and oxidative stress in epilepsy. J Adv Med Pharm Sci 2016,10(1),1-9","journal-title":"J Adv Med Pharm Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1073858414529828","volume":"21","author":"Dal Pr\u00e0 I.","year":"2015","unstructured":"Dal Pr\u00e0 I.; Chiarini A.; Gui L.; Do astrocytes collaborate with neurons in spreading the \u201cinfectious\u201d a\u03b2 and Tau drivers of Alzheimer\u2019s disease? Neuroscientist 2015,21(1),9-29","journal-title":"Neuroscientist"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4018\/978-1-7998-1317-0.ch014","author":"Pandey M.","year":"2020","unstructured":"Pandey M.; Nabi J.; Tabassum N.; Pottoo F.H.; Khatik R.; Ahmad N.; Molecular chaperones in neurodegeneration: mechanisms of regulation in cellular proteostasis. Quality Control of Cellular Protein in Neurodegenerative 2020,354-379","journal-title":"Quality Control of Cellular Protein in Neurodegenerative"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"Braak H.","year":"1997","unstructured":"Braak H.; Braak E.; Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997,18(4),351-357","journal-title":"Neurobiol Aging"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4018\/978-1-7998-1317-0.ch011","author":"Pandey M.","year":"2020","unstructured":"Pandey M.; Saleem S.; Nautiyal H.; Pottoo F.H.; Javed M.N.; PINK1\/Parkin in neurodegenerative disorders: crosstalk between mitochondrial stress and neurodegeneration. Quality Control of Cellular Protein in Neurodegenerative Disorders 2020,282-301","journal-title":"Quality Control of Cellular Protein in Neurodegenerative Disorders"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1126\/science.aay5188","volume":"365","author":"Selkoe D.J.","year":"2019","unstructured":"Selkoe D.J.; Early network dysfunction in Alzheimer\u2019s disease. Science 2019,365(6453),540-541","journal-title":"Science"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/jnc.12202","volume":"126","author":"Gu L.","year":"2013","unstructured":"Gu L.; Guo Z.; Alzheimer\u2019s A\u03b242 and A\u03b240 peptides form interlaced amyloid fibrils. J Neurochem 2013,126(3),305-311","journal-title":"J Neurochem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","volume":"13","author":"Iwatsubo T.","year":"1994","unstructured":"Iwatsubo T.; Odaka A.; Suzuki N.; Mizusawa H.; Nukina N.; Ihara Y.; Visualization of A \u03b2 42(43) and A \u03b2 40 in senile plaques with end-specific A \u03b2 monoclonals: evidence that an initially deposited species is A \u03b2 42(43). Neuron 1994,13(1),45-53","journal-title":"Neuron"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1034\/j.1600-0404.107.s179.9.x","volume":"107","author":"Andreasen N.","year":"2003","unstructured":"Andreasen N.; Vanmechelen E.; Vanderstichele H.; Davidsson P.; Blennow K.; Cerebrospinal fluid levels of total-tau, phospho-tau and Abeta42 predicts development of Alzheimer\u2019s disease in patients with mild cognitive impairment. Acta Neurol Scand 2003,107(s179),47-51","journal-title":"Acta Neurol Scand"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1471-4159.2005.03578.x","volume":"96","author":"Bentahir M.","year":"2006","unstructured":"Bentahir M.; Nyabi O.; Verhamme J.; Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 2006,96(3),732-742","journal-title":"J Neurochem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/35015193","volume":"405","author":"De Strooper B.","year":"2000","unstructured":"De Strooper B.; Alzheimer\u2019s disease. Closing in on \u03b3-secretase. Nature 2000,405(6787),627-628, 629","journal-title":"Nature"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/359325a0","volume":"359","author":"Seubert P.","year":"1992","unstructured":"Seubert P.; Vigo-Pelfrey C.; Esch F.; Isolation and quantification of soluble Alzheimer\u2019s \u03b2-peptide from biological fluids. Nature 1992,359(6393),325-327","journal-title":"Nature"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1750-3639.1991.tb00661.x","volume":"1","author":"Braak H.","year":"1991","unstructured":"Braak H.; Braak E.; Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991,1(3),213-216","journal-title":"Brain Pathol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/NRL.0b013e31826a998d","volume":"18","author":"Budson A.E.","year":"2012","unstructured":"Budson A.E.; Solomon P.R.; New criteria for Alzheimer disease and mild cognitive impairment: implications for the practicing clinician. Neurologist 2012,18(6),356-363","journal-title":"Neurologist"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"Sabri O.","year":"2015","unstructured":"Sabri O.; Seibyl J.; Rowe C.; Barthel H.; Beta-amyloid imaging with florbetaben. Clin Transl Imaging 2015,3(1),13-26","journal-title":"Clin Transl Imaging"},{"key":"ref=31","first-page":"pp. 1","author":"Maies K.","year":"2015","unstructured":"Maies K.;  \u201cFoxO Proteins in the Nervous System,\u201d Analytical cell Patho 2015,pp. 1-15","journal-title":"\u201cFoxO Proteins in the Nervous System,\u201d Analytical cell Patho"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","volume":"4","author":"Hampel H.","year":"2008","unstructured":"Hampel H.; B\u00fcrger K.; Teipel S.J.; Bokde A.L.W.; Zetterberg H.; Blennow K.; Core candidate neurochemical and imaging biomarkers of Alzheimer\u2019s disease. Alzheimers Dement 2008,4(1),38-48","journal-title":"Alzheimers Dement"},{"key":"ref=33","first-page":"57","volume":"5","author":"Koola M M","year":"2018","unstructured":"Koola M M; Nikiforuk A; Pillai A; Parsaik A K;  Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer\u2019s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity J Geriatr care Res 2018,5(2),57-67","journal-title":"Galantamine-memantine combination superior to donepezil-memantine combination in Alzheimer\u2019s disease: critical dissection with an emphasis on kynurenic acid and mismatch negativity J Geriatr care Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/1061186X.2018.1474361","volume":"27","author":"Lao K.","year":"2019","unstructured":"Lao K.; Ji N.; Zhang X.; Qiao W.; Tang Z.; Gou X.; Drug development for Alzheimer\u2019s disease.: review J Drug Target 2019,27(2),164-173","journal-title":"J Drug Target"},{"key":"ref=35","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/625659","volume":"2015","author":"Dong H.","year":"2015","unstructured":"Dong H.; Li J.; Huang L.; Serum microrna profiles serve as novel biomarkers for the diagnosis of Alzheimer\u2019s disease. Dis Markers 2015,2015","journal-title":"Dis Markers"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","volume":"68","author":"Auld D.S.","year":"2002","unstructured":"Auld D.S.; Kornecook T.J.; Bastianetto S.; Quirion R.; Alzheimer\u2019s disease and the basal forebrain cholinergic system: relations to \u03b2-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002,68(3),209-245","journal-title":"Prog Neurobiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"Bateman R.J.","year":"2012","unstructured":"Bateman R.J.; Xiong C.; Benzinger T.L.; Dominantly inherited Alzheimer network.clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med 2012,367(9),795-804","journal-title":"N Engl J Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/alzrt214","volume":"5","author":"Pooler A.M.","year":"2013","unstructured":"Pooler A.M.; Polydoro M.; Wegmann S.; Nicholls S.B.; Spires-Jones T.L.; Hyman B.T.; Propagation of tau pathology in Alzheimer\u2019s disease: identification of novel therapeutic targets. Alzheimers Res Ther 2013,5(5),49","journal-title":"Alzheimers Res Ther"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"Salloway S.","year":"2014","unstructured":"Salloway S.; Sperling R.; Fox N.C.; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 2014,370(4),322-333","journal-title":"N Engl J Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"Doody R.S.","year":"2014","unstructured":"Doody R.S.; Thomas R.G.; Farlow M.; Alzheimer\u2019s Disease Cooperative Study Steering Committee; Solanezumab Study Group.Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 2014,370(4),311-321","journal-title":"N Engl J Med"},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"Kennedy ME","year":"2016","unstructured":"Kennedy ME; Stamford AW; Chen1 X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS -amyloid in animal models and in Alzheimers disease patients. Sci Transl Med 2016,8(363)","journal-title":"Sci Transl Med"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1586\/14737175.2015.996551","volume":"15","author":"Perry D.","year":"2015","unstructured":"Perry D.; Sperling R.; Katz R.; Building a roadmap for developing combination therapies for Alzheimer\u2019s disease. Expert Rev Neurother 2015,15(3),327-333","journal-title":"Expert Rev Neurother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","volume":"21","author":"Pedersen J.T.","year":"2015","unstructured":"Pedersen J.T.; Sigurdsson E.M.; Tau immunotherapy for Alzheimer\u2019s disease. Trends Mol Med 2015,21(6),394-402","journal-title":"Trends Mol Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2174\/1567205011310030001","volume":"10","author":"Rosenmann H.","year":"2013","unstructured":"Rosenmann H.; Immunotherapy for targeting tau pathology in Alzheimer\u2019s disease and tauopathies. Curr Alzheimer Res 2013,10(3),217-228","journal-title":"Curr Alzheimer Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-neuro-062111-150444","volume":"35","author":"Buzs\u00e1ki G.","year":"2012","unstructured":"Buzs\u00e1ki G.; Wang X-J.; Mechanisms of gamma oscillations. Annu Rev Neurosci 2012,35(1),203-225","journal-title":"Annu Rev Neurosci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/imt-2016-0019","volume":"8","author":"Panza F.","year":"2016","unstructured":"Panza F.; Solfrizzi V.; Seripa D.; Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy. Immunotherapy 2016,8(9),1119-1134","journal-title":"Immunotherapy"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.arcmed.2012.11.008","volume":"43","author":"Ramirez-Bermudez J.","year":"2012","unstructured":"Ramirez-Bermudez J.; Alzheimer\u2019s disease: critical notes on the history of a medical concept. Arch Med Res 2012,43(8),595-599","journal-title":"Arch Med Res"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13195-014-0089-7","volume":"6","author":"Vassar R.","year":"2014","unstructured":"Vassar R.; BACE1 inhibitor drugs in clinical trials for Alzheimer\u2019s disease. Alzheimers Res Ther 2014,6(9),89","journal-title":"Alzheimers Res Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1326-6-31","volume":"6","author":"Ertekin-Taner N.","year":"2011","unstructured":"Ertekin-Taner N.; Gene expression endophenotypes: a novel approach for gene discovery in Alzheimer\u2019s disease. Mol Neurodegener 2011,6(1),31","journal-title":"Mol Neurodegener"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12035-010-8109-5","volume":"41","author":"Eckert A.","year":"2010","unstructured":"Eckert A.; Schulz K.L.; Rhein V.; G\u00f6tz J.; \n                       Convergence of amyloid-beta and tau pathologies on mitochondria \n                        \n                           in vivo\n                        \n                       .\n                     Mol Neurobiol 2010,41(2-3),107-114","journal-title":"Mol Neurobiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1086\/504044","volume":"78","author":"Theuns J.","year":"2006","unstructured":"Theuns J.; Brouwers N.; Engelborghs S.; Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 2006,78(6),936-946","journal-title":"Am J Hum Genet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.neurobiolaging.2006.10.001","volume":"29","author":"Lv H.","year":"2008","unstructured":"Lv H.; Jia L.; Jia J.; Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer\u2019s disease. Neurobiol Aging 2008,29(2),194-202","journal-title":"Neurobiol Aging"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/34910","volume":"391","author":"De Strooper B.","year":"1998","unstructured":"De Strooper B.; Saftig P.; Craessaerts K.; Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 1998,391(6665),387-390","journal-title":"Nature"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"822","DOI":"10.2741\/2723","volume":"13","author":"Das H.K.","year":"2008","unstructured":"Das H.K.; Transcriptional regulation of the presenilin-1 gene: implication in Alzheimer\u2019s disease. Front Biosci 2008,13(13),822-832","journal-title":"Front Biosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-6606-6-44","volume":"6","author":"Chen X-F.","year":"2013","unstructured":"Chen X-F.; Zhang Y.W.; Xu H.; Bu G.; Transcriptional regulation and its misregulation in Alzheimer\u2019s disease. Mol Brain 2013,6(1),44","journal-title":"Mol Brain"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1211103","volume":"368","author":"Jonsson T.","year":"2013","unstructured":"Jonsson T.; Stefansson H.; Steinberg S.; Variant of TREM2 associated with the risk of Alzheimer\u2019s disease. N Engl J Med 2013,368(2),107-116","journal-title":"N Engl J Med"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.4049\/jimmunol.177.6.3520","volume":"177","author":"Turnbull I.R.","year":"2006","unstructured":"Turnbull I.R.; Gilfillan S.; Cella M.; Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 2006,177(6),3520-3524","journal-title":"J Immunol"},{"key":"ref=58","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2014.00046","volume":"7","author":"Llorens-Mar\u00edtin M.","year":"2014","unstructured":"Llorens-Mar\u00edtin M.; Jurado J.; Hern\u00e1ndez F.; \u00c1vila J.; GSK-3\u03b2, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 2014,7","journal-title":"Front Mol Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/toxsci\/kfh254","volume":"82","author":"Milano J.","year":"2004","unstructured":"Milano J.; McKay J.; Dagenais C.; Modulation of notch processing by \u03b3-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004,82(1),341-358","journal-title":"Toxicol Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0891-0618(99)00012-5","volume":"16","author":"Leroy K.","year":"1999","unstructured":"Leroy K.; Brion J-P.; Developmental expression and localization of glycogen synthase kinase-3\u03b2 in rat brain. J Chem Neuroanat 1999,16(4),279-293","journal-title":"J Chem Neuroanat"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S1097-2765(01)00253-2","volume":"7","author":"Frame S.","year":"2001","unstructured":"Frame S.; Cohen P.; Biondi R.M.; A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001,7(6),1321-1327","journal-title":"Mol Cell"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1126\/science.275.5300.661","volume":"25","author":"Dudek H.","year":"1997","unstructured":"Dudek H.; Regulation of neuronal survival by the serine-threonine protein kinase akt. Science 1997,25(5300),661-665","journal-title":"Science"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/364412a0","volume":"364","author":"Clark K.L.","year":"1993","unstructured":"Clark K.L.; Halay E.D.; Lai E.; Burley S.K.; Co-crystal structure of the HNF-3\/fork head DNA-recognition motif resembles histone H5. Nature 1993,364(6436),412-420","journal-title":"Nature"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.molmed.2008.03.002","volume":"14","author":"Maiese K.","year":"2008","unstructured":"Maiese K.; Chong Z.Z.; Shang Y.C.; OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008,14(5),219-227","journal-title":"Trends Mol Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1242\/jcs.001222","volume":"120","author":"Huang H.","year":"2007","unstructured":"Huang H.; Tindall D.J.; Dynamic FoxO transcription factors. J Cell Sci 2007,120(Pt 15),2479-2487","journal-title":"J Cell Sci"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1517\/14728222.2012.719499","volume":"16","author":"Maiese K.","year":"2012","unstructured":"Maiese K.; Chong Z.Z.; Shang Y.C.; Wang S.; Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets 2012,16(12),1203-1214","journal-title":"Expert Opin Ther Targets"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1093\/molbev\/msw193","volume":"33","author":"Park Y.","year":"2016","unstructured":"Park Y.; Nnamani M.C.; Maziarz J.; Wagner G.P.; Cis-regulatory evolution of forkhead box O1 (FOXO1), a terminal selector gene for decidual stromal cell identity. Mol Biol Evol 2016,33(12),3161-3169","journal-title":"Mol Biol Evol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/978-1-4419-1599-3_18","volume":"665","author":"Maiese K.","year":"2009","unstructured":"Maiese K.; Chong Z.Z.; Hou J.; Shang Y.C.; The \u201cO\u201d class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol 2009,665,242-260","journal-title":"Adv Exp Med Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1042\/BJ20050525","volume":"391","author":"van der Heide L.P.","year":"2005","unstructured":"van der Heide L.P.; Jacobs F.M.J.; Burbach J.P.H.; Hoekman M.F.M.; Smidt M.P.; FoxO6 transcriptional activity is regulated by Thr26 and Ser184, independent of nucleo-cytoplasmic shuttling. Biochem J 2005,391(Pt 3),623-629","journal-title":"Biochem J"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1101\/gad.208926.112","volume":"26","author":"Salih D.A.M.","year":"2012","unstructured":"Salih D.A.M.; Rashid A.J.; Colas D.; FoxO6 regulates memory consolidation and synaptic function. Genes Dev 2012,26(24),2780-2801","journal-title":"Genes Dev"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2174\/156720211796558069","volume":"8","author":"Hou J.","year":"2011","unstructured":"Hou J.; Wang S.; Shang Y.C.; Chong Z.Z.; Maiese K.; Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res 2011,8(3),220-235","journal-title":"Curr Neurovasc Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1523\/JNEUROSCI.2444-14.2015","volume":"35","author":"Peng S.","year":"2015","unstructured":"Peng S.; Zhao S.; Yan F.; HDAC2 selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. J Neurosci 2015,35(3),1250-1259","journal-title":"J Neurosci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.bbamcr.2013.04.006","volume":"1833","author":"Chamorro M.E.","year":"2013","unstructured":"Chamorro M.E.; Wenker S.D.; Vota D.M.; Vittori D.C.; Nesse A.B.; Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative. Biochim Biophys Acta 2013,1833(8),1960-1968","journal-title":"Biochim Biophys Acta"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"24700","DOI":"10.1074\/jbc.M114.567321","volume":"289","author":"Zeldich E.","year":"2014","unstructured":"Zeldich E.; Chen C.D.; Colvin T.A.; \n                       The neuroprotective effect of Klotho is mediated \n                        \n                           via \n                        \n                       regulation of members of the redox system.\n                     J Biol Chem 2014,289(35),24700-24715","journal-title":"J Biol Chem"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.neuroscience.2013.09.030","volume":"255","author":"Rong Z.","year":"2013","unstructured":"Rong Z.; Pan R.; Xu Y.; Zhang C.; Cao Y.; Liu D.; Hesperidin pretreatment protects hypoxia-ischemic brain injury in neonatal rat. Neuroscience 2013,255,292-299","journal-title":"Neuroscience"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fphar.2012.00015","volume":"3","author":"Neri C.","year":"2012","unstructured":"Neri C.; Role and therapeutic potential of the pro-longevity factor FOXO and its regulators in neurodegenerative disease. Front Pharmacol 2012,3,15","journal-title":"Front Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.modgep.2005.07.003","volume":"6","author":"Hoekman M.F.M.","year":"2006","unstructured":"Hoekman M.F.M.; Jacobs F.M.J.; Smidt M.P.; Burbach J.P.H.; Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns 2006,6(2),134-140","journal-title":"Gene Expr Patterns"},{"key":"ref=78","first-page":"357","volume":"2","author":"Glenner G.G.","year":"1984","unstructured":"Glenner G.G.; Wong C.W.; Quaranta V.; Eanes E.D.; The amyloid deposits in Alzheimer\u2019s disease: their nature and pathogenesis. Appl Pathol 1984,2(6),357-369","journal-title":"Appl Pathol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","volume":"76","author":"Anand R","year":"2014","unstructured":"Anand R; Gill KD; Mahdi AA; Therapeutics of Alzheimer\u2019s disease: past, present and future. Neuropharmacology 2014,76(Pt A),27-50","journal-title":"Neuropharmacology"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/emboj\/20.1.27","volume":"20","author":"Lucas J.J.","year":"2001","unstructured":"Lucas J.J.; Hern\u00e1ndez F.; G\u00f3mez-Ramos P.; Mor\u00e1n M.A.; Hen R.; Avila J.; Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001,20(1-2),27-39","journal-title":"EMBO J"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1021\/bi970982t","volume":"37","author":"Bullock B.P.","year":"1998","unstructured":"Bullock B.P.; Habener J.F.; Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry 1998,37(11),3795-3809","journal-title":"Biochemistry"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"37436","DOI":"10.1074\/jbc.M105725200","volume":"276","author":"Bijur G.N.","year":"2001","unstructured":"Bijur G.N.; Jope R.S.; Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 \u03b2. J Biol Chem 2001,276(40),37436-37442","journal-title":"J Biol Chem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3233\/JAD-2010-1317","volume":"19","author":"Qian W.","year":"2010","unstructured":"Qian W.; Shi J.; Yin X.; PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis 2010,19(4),1221-1229","journal-title":"J Alzheimers Dis"},{"key":"ref=84","first-page":"408","volume":"16","author":"Alikhani M.","year":"2010","unstructured":"Alikhani M.; Roy S.; Graves D.T.; FOXO1 plays an essential role in apoptosis of retinal pericytes. Mol Vis 2010,16,408-415","journal-title":"Mol Vis"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"C850","DOI":"10.1152\/ajpcell.00356.2006","volume":"292","author":"Alikhani M.","year":"2007","unstructured":"Alikhani M.; Maclellan C.M.; Raptis M.; Vora S.; Trackman P.C.; Graves D.T.; Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 2007,292(2),C850-C856","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/hep.22526","volume":"48","author":"Speckmann B.","year":"2008","unstructured":"Speckmann B.; Walter P.L.; Alili L.; Selenoprotein P expression is controlled through interaction of the coactivator PGC-1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. Hepatology 2008,48(6),1998-2006","journal-title":"Hepatology"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1113\/expphysiol.2012.068361","volume":"98","author":"Lu Q.","year":"2013","unstructured":"Lu Q.; Zhai Y.; Cheng Q.; The Akt-FoxO3a-manganese superoxide dismutase pathway is involved in the regulation of oxidative stress in diabetic nephropathy. Exp Physiol 2013,98(4),934-945","journal-title":"Exp Physiol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1083\/jcb.200410041","volume":"169","author":"Smith W.W.","year":"2005","unstructured":"Smith W.W.; Norton D.D.; Gorospe M.; Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol 2005,169(2),331-339","journal-title":"J Cell Biol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/156720209787466064","volume":"6","author":"Shang Y.C.","year":"2009","unstructured":"Shang Y.C.; Chong Z.Z.; Hou J.; Maiese K.; The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through Caspase 3. Curr Neurovasc Res 2009,6(1),20-31","journal-title":"Curr Neurovasc Res"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023566","volume":"6","author":"Chuang P.Y.","year":"2011","unstructured":"Chuang P.Y.; Dai Y.; Liu R.; Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011,6(8)","journal-title":"PLoS One"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.1128\/MCB.01748-06","volume":"27","author":"Li H.","year":"2007","unstructured":"Li H.; Liang J.; Castrillon D.H.; DePinho R.A.; Olson E.N.; Liu Z-P.; FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol 2007,27(7),2676-2686","journal-title":"Mol Cell Biol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/sj.onc.1208352","volume":"24","author":"Yang H.","year":"2005","unstructured":"Yang H.; Zhao R.; Yang H-Y.; Lee M-H.; Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene 2005,24(11),1924-1935","journal-title":"Oncogene"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1101\/gad.1880510","volume":"24","author":"de la Torre-Ubieta L.","year":"2010","unstructured":"de la Torre-Ubieta L.; Gaudilli\u00e8re B.; Yang Y.; A FOXO-Pak1 transcriptional pathway controls neuronal polarity. Genes Dev 2010,24(8),799-813","journal-title":"Genes Dev"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.2337\/db11-0548","volume":"60","author":"Kim D.H.","year":"2011","unstructured":"Kim D.H.; Perdomo G.; Zhang T.; FoxO6 integrates insulin signaling with gluconeogenesis in the liver. Diabetes 2011,60(11),2763-2774","journal-title":"Diabetes"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"19547","DOI":"10.1074\/jbc.272.31.19547","volume":"272","author":"Hong M.","year":"1997","unstructured":"Hong M.; Lee V.M-Y.; Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 1997,272(31),19547-19553","journal-title":"J Biol Chem"},{"key":"ref=96","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101645","volume":"181","author":"Hu W.","year":"2019","unstructured":"Hu W.; Yang Z.; Yang W.; Roles of forkhead box O (FoxO) transcription factors in neurodegenerative diseases: a panoramic view. Prog Neurobiol 2019,181","journal-title":"Prog Neurobiol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbrc.2012.01.122","volume":"419","author":"Hong Y.K.","year":"2012","unstructured":"Hong Y.K.; Lee S.; Park S.H.; Inhibition of JNK\/dFOXO pathway and caspases rescues neurological impairments in Drosophila Alzheimer\u2019s disease model. Biochem Biophys Res Commun 2012,419(1),49-53","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-131544","volume":"40","author":"Perez F.P.","year":"2014","unstructured":"Perez F.P.; Bose D.; Maloney B.; Nho K.; Shah K.; Lahiri D.K.; Late-onset Alzheimer\u2019s disease, heating up and foxed by several proteins: pathomolecular effects of the aging process. J Alzheimers Dis 2014,40(1),1-17","journal-title":"J Alzheimers Dis"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.neuropharm.2015.08.020","volume":"99","author":"Wang H.","year":"2015","unstructured":"Wang H.; Quirion R.; Little P.J.; Forkhead box O transcription factors as possible mediators in the development of major depression. Neuropharmacology 2015,99,527-537","journal-title":"Neuropharmacology"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"10812","DOI":"10.1074\/jbc.M113.519355","volume":"289","author":"Akhter R.","year":"2014","unstructured":"Akhter R.; Sanphui P.; Biswas S.C.; The essential role of p53-up-regulated modulator of apoptosis (Puma) and its regulation by FoxO3a transcription factor in \u03b2-amyloid-induced neuron death. J Biol Chem 2014,289(15),10812-10822","journal-title":"J Biol Chem"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1074\/jbc.M116.744730","volume":"292","author":"Saleem S.","year":"2017","unstructured":"Saleem S.; Biswas S.C.; Tribbles pseudokinase 3 induces both apoptosis and autophagy in amyloid-\u03b2-induced neuronal death. J Biol Chem 2017,292(7),2571-2585","journal-title":"J Biol Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neulet.2015.10.001","volume":"609","author":"Fluteau A.","year":"2015","unstructured":"Fluteau A.; Ince P.G.; Minett T.; MRC Cognitive Function Ageing Neuropathology Study Group. The nuclear retention of transcription factor FOXO3a correlates with a DNA damage response and increased glutamine synthetase expression by astrocytes suggesting a neuroprotective role in the ageing brain. Neurosci Lett 2015,609,11-17","journal-title":"Neurosci Lett"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neurobiolaging.2013.07.019","volume":"35","author":"Kuang X.","year":"2014","unstructured":"Kuang X.; Chen Y.S.; Wang L.F.; Klotho upregulation contributes to the neuroprotection of ligustilide in an Alzheimer\u2019s disease mouse model. Neurobiol Aging 2014,35(1),169-178","journal-title":"Neurobiol Aging"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","volume":"40","author":"Ciechanover A.","year":"2003","unstructured":"Ciechanover A.; Brundin P.; The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 2003,40(2),427-446","journal-title":"Neuron"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1172\/JCI33585","volume":"118","author":"Pickford F.","year":"2008","unstructured":"Pickford F.; Masliah E.; Britschgi M.; The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid \u03b2 accumulation in mice. J Clin Invest 2008,118(6),2190-2199","journal-title":"J Clin Invest"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nature04724","volume":"441","author":"Hara T.","year":"2006","unstructured":"Hara T.; Nakamura K.; Matsui M.; Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006,441(7095),885-889","journal-title":"Nature"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2010.10.007","volume":"143","author":"Demontis F.","year":"2010","unstructured":"Demontis F.; Perrimon N.; FOXO\/4E-BP signaling in Drosophila muscles regulates organism-wide proteostasis during aging. Cell 2010,143(5),813-825","journal-title":"Cell"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"28319","DOI":"10.1074\/jbc.M109.024406","volume":"284","author":"Sengupta A.","year":"2009","unstructured":"Sengupta A.; Molkentin J.D.; Yutzey K.E.; FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 2009,284(41),28319-28331","journal-title":"J Biol Chem"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tibs.2014.02.003","volume":"39","author":"Webb A.E.","year":"2014","unstructured":"Webb A.E.; Brunet A.; FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci 2014,39(4),159-169","journal-title":"Trends Biochem Sci"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.abb.2003.10.010","volume":"421","author":"Husom A.D.","year":"2004","unstructured":"Husom A.D.; Peters E.A.; Kolling E.A.; Fugere N.A.; Thompson L.V.; Ferrington D.A.; Altered proteasome function and subunit composition in aged muscle. Arch Biochem Biophys 2004,421(1),67-76","journal-title":"Arch Biochem Biophys"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/nature11468","volume":"489","author":"Vilchez D.","year":"2012","unstructured":"Vilchez D.; Boyer L.; Morantte I.; Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature 2012,489(7415),304-308","journal-title":"Nature"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1101\/gad.14.2.142","volume":"14","author":"Kaestner K.H.","year":"2000","unstructured":"Kaestner K.H.; Kno W.; Mart\u0131 D.E.; Unified nomenclature for the winged helix: forkhead transcription factors. Genes Dev 2000,14(2),142-146","journal-title":"Genes Dev"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj20040167","volume":"380","author":"Van Der Heide L.P.","year":"2004","unstructured":"Van Der Heide L.P.; Hoekman F.M.; Smidt M.P.; The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004,380(2),297-309","journal-title":"Biochem J"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"15982","DOI":"10.1074\/jbc.274.23.15982","volume":"274","author":"Nakae J.","year":"1999","unstructured":"Nakae J.; Park B-C.; Accili D.; Insulin stimulates phosphorylation of the forkhead transcription factor FKHR on serine 253 through a Wortmannin-sensitive pathway. J Biol Chem 1999,274(23),15982-15985","journal-title":"J Biol Chem"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/emboj\/21.9.2263","volume":"21","author":"Rena G.","year":"2002","unstructured":"Rena G.; Woods Y.L.; Prescott A.R.; Two novel phosphorylation sites on FKHR that are critical for its nuclear exclusion. EMBO J 2002,21(9),2263-2271","journal-title":"EMBO J"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1042\/bj3540605","volume":"354","author":"Rena G.","year":"2001","unstructured":"Rena G.; Prescott A.R.; Guo S.; Cohen P.; Unterman T.G.; Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation sites in regulating 14-3-3 binding, transactivation and nuclear targetting. Biochem J 2001,354(Pt 3),605-612","journal-title":"Biochem J"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1073\/pnas.0406789102","volume":"102","author":"Huang H.","year":"2005","unstructured":"Huang H.; Regan K.M.; Wang F.; Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA 2005,102(5),1649-1654","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"11285","DOI":"10.1073\/pnas.1934283100","volume":"100","author":"Matsuzaki H.","year":"2003","unstructured":"Matsuzaki H.; Daitoku H.; Hatta M.; Tanaka K.; Fukamizu A.; Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc Natl Acad Sci USA 2003,100(20),11285-11290","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"15581","DOI":"10.1074\/jbc.M115.650994","volume":"290","author":"Calabuig-Navarro V.","year":"2015","unstructured":"Calabuig-Navarro V.; Yamauchi J.; Lee S.; Forkhead box O6 (FoxO6) depletion attenuates hepatic gluconeogenesis and protects against fat-induced glucose disorder in mice. J Biol Chem 2015,290(25),15581-15594","journal-title":"J Biol Chem"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1748-1716.2007.01780.x","volume":"192","author":"Greer E.L.","year":"2008","unstructured":"Greer E.L.; Brunet A.; FOXO transcription factors in ageing and cancer. Acta Physiol (Oxf) 2008,192(1),19-28","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1464-5491.2005.01566.x","volume":"22","author":"Schinner S.","year":"2005","unstructured":"Schinner S.; Scherbaum W.A.; Bornstein S.R.; Barthel A.; Molecular mechanisms of insulin resistance. Diabet Med 2005,22(6),674-682","journal-title":"Diabet Med"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-2008-15313","volume":"15","author":"Bellinger F.P.","year":"2008","unstructured":"Bellinger F.P.; He Q.P.; Bellinger M.T.; Association of selenoprotein p with Alzheimer\u2019s pathology in human cortex. J Alzheimers Dis 2008,15(3),465-472","journal-title":"J Alzheimers Dis"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neuroscience.2008.01.044","volume":"153","author":"Sompol P.","year":"2008","unstructured":"Sompol P.; Ittarat W.; Tangpong J.; A neuronal model of Alzheimer\u2019s disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience 2008,153(1),120-130","journal-title":"Neuroscience"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","volume":"29","author":"Jope R.S.","year":"2004","unstructured":"Jope R.S.; Johnson G.V.; The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004,29(2),95-102","journal-title":"Trends Biochem Sci"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"30479","DOI":"10.1074\/jbc.M607468200","volume":"281","author":"Liang M-H.","year":"2006","unstructured":"Liang M-H.; Chuang D-M.; Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 2006,281(41),30479-30484","journal-title":"J Biol Chem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s004010050513","volume":"92","author":"Yamaguchi H.","year":"1996","unstructured":"Yamaguchi H.; Ishiguro K.; Uchida T.; Takashima A.; Lemere C.A.; Imahori K.; Preferential labeling of Alzheimer neurofibrillary tangles with antisera for Tau Protein Kinase (TPK) I\/glycogen synthase kinase-3 \u03b2 and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol 1996,92(3),232-241","journal-title":"Acta Neuropathol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S0002-9440(10)63465-7","volume":"163","author":"Ishizawa T.","year":"2003","unstructured":"Ishizawa T.; Sahara N.; Ishiguro K.; Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 2003,163(3),1057-1067","journal-title":"Am J Pathol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature01640","volume":"423","author":"Phiel C.J.","year":"2003","unstructured":"Phiel C.J.; Wilson C.A.; Lee V.M-Y.; Klein P.S.; GSK-3\u03b1 regulates production of Alzheimer\u2019s disease amyloid-\u03b2 peptides. Nature 2003,423(6938),435-439","journal-title":"Nature"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4018\/978-1-7998-1317-0.ch009","author":"Kareem O.","year":"2020","unstructured":"Kareem O.; Ghulam Nabi Bader, Faheem Hyder Pottoo, Mohd Amir, Md. Abul Barkat, Mukesh Pandey. Beclin 1 complex and neurodegenerative disorders. Quality Control of Cellular Protein in Neurodegenerative Disorders 2020,236-260","journal-title":"Quality Control of Cellular Protein in Neurodegenerative Disorders"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1097-2765(02)00482-3","volume":"9","author":"Shi Y.","year":"2002","unstructured":"Shi Y.; Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell 2002,9(3),459-470","journal-title":"Mol Cell"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0002-9440(10)63317-2","volume":"165","author":"Guo H.","year":"2004","unstructured":"Guo H.; Albrecht S.; Bourdeau M.; Petzke T.; Bergeron C.; LeBlanc A.C.; Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer\u2019s disease. Am J Pathol 2004,165(2),523-531","journal-title":"Am J Pathol"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI200420640","volume":"114","author":"Rissman R.A.","year":"2004","unstructured":"Rissman R.A.; Poon W.W.; Blurton-Jones M.; Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 2004,114(1),121-130","journal-title":"J Clin Invest"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"Oddo S.","year":"2003","unstructured":"Oddo S.; Caccamo A.; Shepherd J.D.; Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003,39(3),409-421","journal-title":"Neuron"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1463-1326.2007.00782.x","volume":"9","author":"Buteau J.","year":"2007","unstructured":"Buteau J.; Accili D.; Regulation of pancreatic beta-cell function by the forkhead protein FoxO1. Diabetes Obes Metab 2007,9(s2)(Suppl. 2),140-146","journal-title":"Diabetes Obes Metab"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"846","DOI":"10.2337\/db07-0595","volume":"57","author":"Martinez S.C.","year":"2008","unstructured":"Martinez S.C.; Tanabe K.; Cras-M\u00e9neur C.; Abumrad N.A.; Bernal-Mizrachi E.; Permutt M.A.; Inhibition of Foxo1 protects pancreatic islet beta-cells against fatty acid and endoplasmic reticulum stress-induced apoptosis. Diabetes 2008,57(4),846-859","journal-title":"Diabetes"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186445\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T10:36:44Z","timestamp":1638700604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186445\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":135,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,12,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319666201001105553","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}